The cantons of Zug and Solothurn in the Greater Zurich Area are ideal locations for Biogen’s international headquarters due to the favorable environment it provides for businesses and employees.
Biogen is where science meets humanity. As pioneers in neuroscience, the company has developed the world’s leading portfolio of treatments for Multiple Sclerosis and developed the world’s first approved treatment for Spinal Muscular Atrophy. Today, Biogen is developing innovative treatments for Alzheimer’s Disease, ALS, and many other conditions. Biogen established its international headquarters in the Greater Zurich Area in 2004. Since then the company has grown to more than 500 permanent employees based in Baar, Zug. In 2023, the company further opened a next-generation manufacturing facility in Solothurn, which offers space for more than 500 employees.
The perfect match
Switzerland was an obvious choice for Biogen due to its political stability, predictability, and business-friendly environment. The country also has a long tradition in pharmaceutical development and a strong track record of fostering innovation. Greater Zurich Area's central location in Europe and the excellent connectivity by train and air to the most important European markets have helped Biogen develop its business across the region. Biogen has also valued Switzerland as a home to experienced, well-educated, and highly diverse talent.
Commitment to science
In keeping with Biogen’s commitment to inspiring young people to consider innovative careers in science, the international headquarters has developed and cultivated long-standing relationships with some of the premier STEM (science, technology, education and math) programs in Switzerland including Swiss Science Center Technorama.
